Karger Publishers –
125 Years of Experience
in Medical and
Scientific Publishing

■ Festschrift
Karger – Connecting the World of Biomedical Science
This richly illustrated Festschrift chronicles
the company’s development and contributions in
the service of medicine and science since 1890.
It tells the history of Karger Publishers until the
present day.
Please send an e-mail to 125years@karger.com to
receive your free copy or discover it online.
www.karger.com/festschrift

Publishing Highlights 1890–2015
Take a guided tour through 125 years of medical and scientific publishing!
Follow us on a leisurely walk through interesting times, fascinating topics and
beautiful illustrations.
www.karger.com/highlights

Karger Gazette
The Karger Gazette anniversary issue explores the STM publishing business
in the digital age, offers short portraits of Karger’s journal and book series
editors as well as interviews with three renowned scientists.
www.karger.com/gazette
Guidelines for Authors

Submission
Manuscripts for the sections
Clinical Practice
Experimental Nephrology and Genetics
Physiology
should be submitted online at
www.karger.com/nef

Only papers written in English are considered. Detailed Online Submission Instructions with a link to the Submission Website are at www.karger.com/nef. Before submitting a manuscript, authors are encouraged to review the detailed guidelines at www.karger.com/nef-guidelines for specific directions as to how to get a manuscript ready for submission.

Should you experience problems with your submission, please contact the Managing Editor, Manuela Passera, at the Editorial Office
E-Mail manuela.passera@marionegri.it
Tel. +39 035 4213405
Fax +39 035 319331

Original papers: Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated.

Clinical trial protocols will only be considered if the trial has been fully registered (see A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation below).

Review/Minierview: Are to be submitted only by invitation, although prospective authors are welcome to contact the Managing Editor to discuss whether a topic might be suitable for a Review. The maximum length of a Review/Minierview should be 1,500/2,500 words including abstract and discussion, excluding figure legends and references (50/25 references maximum).

Editorial and Second Opinion: Are to be submitted only by invitation. The maximum length of an Editorial/Second Opinion article should be 1,500/2,500 words including abstract, integrated discussion, excluding references (25/40 references maximum).

Case Reports: Neprhon does not publish case reports. The authors of case reports are invited to submit their manuscript to the Open Access journal Case Reports in Nephrology and Dialysis at www.karger.com/cnd.

Conditions and review
All manuscripts are subject to independent and editorial review. Upon submission, each manuscript is evaluated by the editors and the authors are informed whether the manuscript will be further processed. Before being forwarded to the Associate Editors and reviewers, the presentation of the paper (organization of the results, quality of the figures, overall writing quality, etc.) is assessed and summarized in a Presentation Report that is fair, professional and standardized. The Presentation Report follows the manuscript throughout the peer review and supports editors, reviewers, and authors in the review process. The Editors and Associate Editors carefully analyse the comments of the reviewers in order to provide the authors with constructive and realistic requests that should be feasible within the 12 weeks of revision time. The requests made to the authors by the editors are aimed to improve the robustness and significance of the data presented in the manuscript, while curtailing excessive demands in terms of effort, time and cost.

Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Neprhon and may not be reprinted by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a choice for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Arrangement
Title page: The first page of each paper should indicate the title, the author’s names, the institute where the work was conducted, a short title for use as running head (max. 80 characters), the word count and the total number of references.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Units: Neprhon requires that all articles be submitted with data in SI units and gravimetric units.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 250 words. It should be structured as follows:

Background/ Aim: What is the major problem that prompted the study?

Methods:

Results:

Conclusion: Most important conclusion

Footnotes: Avoid footnotes.

Tables and illustrations: Tables are part of the text. Place them at the end of the text file. Illustration data must be stored as separate files. Do not integrate figures into the text. Electronic submission of high-quality files should be ensured. All illustrations must have a final resolution of 300 dpi after scaling, line drawings of 800–1,200 dpi.

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be listed as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Number references in the order in which they are first mentioned in the text; do not list alphabetically. The surname of the author followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov,.avi,.mpeg).

Author’s Choice
Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed NIH-Funded Research manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating
the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copy-editing and design improvements as well as citation links.

Page Charges/Length of Paper
There are no page charges for papers of 3 or fewer printed pages (including tables, figures, references and acknowledgments). Each additional complete or partial page is charged to the author at CHF 325.00.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to possible delay. Alterations other than the correction of printer’s errors are charged to the author.

A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation
Clinical trials provide important information that can profoundly influence the direction of medical research and clinical care. It is crucial that this process is not unduly influenced by selective publication of clinical trial results. Information regarding all clinical trials should therefore be made available to the general public.

We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. Since 1 April 2006, Nephron no longer accepts manuscripts concerning non-registered trials.

We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase 1 trials) are exempt.

We do not advocate any one particular registry, but registration must be with a registry that meets the following minimum criteria:

• Accessible to the public at no charge.
• Searchable by standard, electronic (internet-based) methods.
• Open to all prospective registrants free of charge or at minimal cost.
• Validates registered information.
• Identifies trials with a unique number.
• Includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons; eligibility criteria, primary and secondary outcomes measured, data of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include:

• The registry sponsored by the US National Library of Medicine www.clinicaltrials.gov
• The International Standard Randomised Controlled Trial Number registry www.isrctn.com
• The Cochrane Renal Group registry www.cochrane-renal.org
• The National (UK) Research Register www.update-software.com/national/
• European Clinical Trials Database https://www.clinicaltrialsgender.eu

Cappuccino with Claudio Ronco

Blood Purification Journal Club

Especially in Italy, but also all over the world, people like to meet over a cappuccino to talk about things like sports or politics before rushing off for work. I would like to invite you to take a cappuccino with me and engage in a conversation on topical issues in nephrology. As part of the ‘Cappuccino with Claudio Ronco’ series, I will monthly select articles recently published in Blood Purification and complement them with an expert comment in the form of a short video posted on the YouTube channel of the International Renal Research Institute of Vicenza and on Karger.com.

Join the Blood Purification Journal Club and enjoy a Cappuccino with Claudio Ronco!
Clinical Practice: Original Papers

233 The Benefit of a Glucose-Sparing PD Therapy on Glycemic Control Measured by Serum Fructosamine in Diabetic Patients in a Randomized, Controlled Trial (IMPENDIA)
Li, P.K.T. (Hong Kong, SAR); Dorval, M. (Moncton, N.B.); Johnson, D.W. (Brisbane, Qld.); Rutherford, P. (Zurich); Shutov, E. (Moscow); Story, K. (Chicago, Ill.); Bargman, J.M. (Toronto, Ont.)

241 Acute Arteriovenous Access Failure: Long-Term Outcomes of Endovascular Salvage and Assessment of Co-Variates Affecting Patency
Nikam, M.D. (Manchester/Singapore); Ritchie, J. (Salford); Jayanti, A.; Bernstein, O.A.; Ebah, L.; Brenchley, P.; Hutchison, A.; Chalmers, N.; Mitra, S. (Manchester)

247 Impact of Vascular Calcifications on Arteriovenous Fistula Survival in Hemodialysis Patients: A Five-Year Follow-Up
Jankovic, A.; Damjanovic, T.; Djuric, Z.; Marinkovic, J. (Belgrade); Schlieper, G. (Aachen); Totic-Dragovic, J.; Djuric, P.; Popovic, J. (Belgrade); Floege, J. (Aachen); Dimkovic, N. (Belgrade)

253 Kidney Volume Estimations with Ellipsoid Equations by Magnetic Resonance Imaging in Autosomal Dominant Polycystic Kidney Disease

263 Examining Determinants of Patient Outcome in a Low Clearance Clinic
Bhatia, R.T. (Kingston Upon Hull); Browne, O.T. (East Yorkshire); Nadeer, S. (Kingston Upon Hull); Allgar, V. (York); Bhandari, S. (Kingston Upon Hull/East Yorkshire)

269 Effect of Membrane Permeability on Cardiovascular Risk Factors and β2m Plasma Levels in Patients on Long-Term Haemodialysis: A Randomised Crossover Trial
Chazot, C. (Sainte Foy Les Lyon); Kirchgessner, J.; Pham, J. (Bad Homburg); Vo-Van, C.; Lorriaux, C.; Hurot, J.-M.; Zaoui, E. (Sainte Foy Les Lyon); Grassmann, A. (Bad Homburg); Jean, G. (Sainte Foy Les Lyon); Marcelli, D. (Bad Homburg)

Clinical Practice: Second Opinion

276 Nephrosclerosis: A Term in Quest of a Disease
Meyrier, A. (Paris)
Experimental Nephrology and Genetics

Fetal Kidney Programming by Maternal Smoking Exposure: Effects on Kidney Structure, Blood Pressure and Urinary Sodium Excretion in Adult Offspring
Block, D.B.; Mesquita, F.F.; de Lima, I.P.; Boer, P.A.; Gontijo, J.A.R. (Campinas)

Serum Klotho: Relation to Fibroblast Growth Factor-23 and Other Regulators of Phosphate Metabolism in Children with Chronic Kidney Disease
Sawires, H.K.; Essam, R.M.; Morgan, M.F.; Mahmoud, R.A. (Cairo)

Physiology

Determination of the Renal Threshold for Glucose Excretion in Familial Renal Glucosuria
Aires, I. (Lisbon); Fila, M. (Paris); Polidori, D. (San Diego, Calif.); Santos, A.R.; Costa, A.B.; Calado, J. (Lisbon)

Contents Vol. 129, 2015
Contents

See the journal website for contents
Program highlights:

- IPNA-ESPN Pre-congress Junior Classes

Outstanding Plenary Speakers

Norbert Lameire
Acute kidney injury: an increasing global concern

Nine Knoers
Genetics in pediatric nephrology: from bench to bedside

Dirk Kuypers
Individualized immunosuppression: myth or reality?

- ERA-EDTA – ESPN 2nd Joint Symposium
- Joint session with European Society of Pediatric Urology
  - CME course on nutrition in CKD
  - CME course on bladder dysfunction (together with ICCS)
- Sparkling cultural and culinary program
Chronic kidney disease is a global major health issue that ultimately leads to end-stage renal disease, a devastating condition requiring costly renal replacement therapy. Given this background, extensive understanding of the pathogenesis of the disease and exploring novel therapeutic targets will help to alleviate disease progression, improve prognosis and reduce its impact on the global economic burden. Currently, primary glomerulonephritis is the leading cause of chronic kidney disease and end-stage renal disease in China and many other countries. Recently, there has been much progress with regard to pathogenesis as well as treatment of primary glomerulonephritis. Clinical data from Chinese studies have significantly contributed to the making of international guidelines and histological classifications of the disease. This book focuses on the cutting-edge knowledge and provides up-to-date information on primary glomerulonephritis. Topics covered are IgA nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, membranoproliferative glomerulonephritis, and crescentic glomerulonephritis.

Contents
Preface: Chen, N.
Overview
• Primary Glomerulonephritis in Mainland China: An Overview: Xie, J.; Chen, N.
• Advances in the Pathology of Glomerular Diseases: Weening, J.J.; Ronco, P.; Remuzzi, G.
• Evaluation of Anemia and Serum iPTH, Calcium, and Phosphorus in Patients with Primary Glomerulonephritis: Li, Y.; Zhang, W.; Ren, H.; Wang, W.; Shi, H.; Li, X.; Chen, X.; Shen, P.; Wu, X.; Xie, J.; Chen, N.

IgA Nephropathy
• Role of Podocyte Injury in IgA Nephropathy: Menon, M.C.; Chuang, P.Y.; He, J.C.
• Genetic Studies of IgA Nephropathy: What Have We Learned from Genome-Wide Association Studies: Xie, J.; Shapiro, S.; Gharavi, A.
• Immunopathological Predictors of Progression in IgA Nephropathy: Tomino, Y.
• Treatment of Progressive IgA Nephropathy: An Update: Wang, W.; Chen, N.

Focal Segmental Glomerulosclerosis
• Minimal Change Disease
• Different Targets for Treating Focal Segmental Glomerular Sclerosis: Coppo, R.
• Screening of ACTN4 and TRPC6 Mutations in a Chinese Cohort of Patients with Adult-Onset Familial Focal Segmental Glomerulosclerosis: Zhang, Q.; Ma, J.; Xie, J.; Wang, Z.; Zhu, B.; Hao, X.; Yang, L.; Ren, H.; Chen, N.
• Increased Risk of Treatment Failure and End-Stage Renal Disease in Familial Segmental Glomerular Sclerosis: Hao, X.; Xie, J.; Ma, J.; Wang, Z.; Zhou, Q.; Yang, L.; Pan, X.; Ren, H.; Chen, N.
• Treatment and Prognosis of Primary Focal Segmental Glomerulosclerosis: Ren, H.; Shen, P.; Li, X.; Pan, X.; Zhang, Q.; Feng, X.; Zhang, W.; Chen, N.

Membranous Nephropathy
• Pathogenesis of Membranous Nephropathy: A New Paradigm in Evolution: Glassock, R.J.
• Short-Term Complications of Membranous Nephropathy: Barbouli, S.; Reich, H.; Cattran, D.
• Tacrolimus Combined with Corticosteroids in Idiopathic Membranous Nephropathy: A Randomized, Prospective, Controlled Trial: Xu, J.; Zhang, W.; Xu, Y.; Shen, P.; Ren, H.; Wang, W.; Li, X.; Pan, X.; Chen, N.

Membranoproliferative Glomerulonephritis
• Membranoproliferative Glomerulonephritis – Mechanisms and Treatment: Appel, G.B.
• Re-Evaluation of the Classification System for Membranoproliferative Glomerulonephritis: Lu, Y.; Shen, P.; Li, X.; Xu, Y.; Pan, X.; Wang, W.; Chen, X.; Zhang, W.; Ren, H.; Chen, N.
• C3 Glomerulopathy: Servais, A.; Noël, L.-H.; Frémeaux-Bacchi, V.; Lesavre, P.
• Hepatitis C Virus-Associated Glomerulonephritis: Tang, S.C.W.; Lai, K.N.

Crescentic Glomerulonephritis
• Pathogenesis of Rapidly Progressive Glomerulonephritis: What Do We Learn? Chen, Y.-X.; Chen, N.
• ANCA-Associated Renal Vasculitis – An Update: Tesar, V.; Hruskova, Z.
• Management of Crescentic Glomerulonephritis: What Are the Recent Advances? Li, X.; Chen, N.
• Plasma Exchange in the Treatment of Rapidly Progressive Glomerulonephritis: Chen, X.; Chen, N.
Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. Blood Purification also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialties.

Blood Purification

Editor-in-Chief
C. Ronco, Vicenza

Blood Purification

Founded: 1983
Category: Clinical Research
Field of Interest: Nephrology

Listed in bibliographic services, including
- Current Contents®
- Pubmed/MEDLINE
- Biological Abstracts
- Excerpta Medica

2015: Volumes 39, 40
4 issues per volume
Language: English
ISSN 0253–5068
e-ISSN 1421–9735

Selected contributions
- Implantable Left Ventricular Assist Devices and the Kidney: Mao, H. (Vicenza/Nanjing); Katz, N. (Baltimore, Md.); Kim, J.C.; Day, S.; Ronco, C. (Vicenza)
- Observational Study of Surveillance Based on the Combination of Online Dialysance and Thermodilution Methods in Hemodialysis Patients with Arteriovenous Fistulas: Fontseré, N.; Mestres, G.; Burrel, M.; Barrufet, M.; Montaña, X.; Arias, M.; Ojeda, R.; Maduell, F.; Campistol, J.M. (Barcelona)
- Post-Dilution High Convective Transport Improves Microinflammation and Endothelial Dysfunction Independently of the Technique: Ariza, F. (Córdoba/Madrid); Merina, A. (Madrid/Barcelona); Carracedo, J.; Alvarez de Lara, M.A. (Córdoba/Madrid); Crespo, R. (Córdoba); Ramirez, R.; Martín-Malo, A.; Aljama, P. (Córdoba/Madrid)
- Coronary Artery Calcification and Outcomes in Diabetic Patients with and without Chronic Kidney Disease: Russo, D. (Naples); Morrone, L.F.P. (Benevento); Imbriaco, M.; Pota, A.; Russo, L.; Scognamiglio, B. (Naples); Sorrentino, R. (Pompei)

More information at www.karger.com/bpu
Karger Publishers – 125 Years of Experience in Medical and Scientific Publishing

Karger Publishers – independent, family-run and Swiss-based.

It is our goal to serve the global scientific community with innovative and outstanding publications in all fields of medical science. This means dedication to maintaining the highest standards of quality, as well as personalized service for authors, editors and readers.

www.karger.com

Please order a free copy of the Karger Festschrift ‘Connecting the World of Biomedical Science’ by sending your address to 125years@karger.com.